Bayer Says It Disagrees With U.S. Supreme Court on Roundup Decision

By Ed Frankl

Bayer AG said Tuesday that it "respectfully disagrees" with the U.S. Supreme Court's decision to decline to hear a review of a case that found that the company's weedkiller Roundup may have caused a Calfornia man's cancer.

The German conglomerate said the Supreme Court's decision not to hear a review of a previous case that awarded Edwin Hardeman $25 million undermines the ability of companies to rely on official actions taken by expert regulatory agencies.

A positive result for Bayer at the Supreme Court could have ended thousands of pending lawsuits against the company.

"Bayer continues to stand fully behind its Roundup products which are a valuable tool in efficient agricultural production around the world," it said.

The Leverkusen-based company said it is prepared to manage the litigation risk associated with potential future claims in the U.S.

Bayer took a provision in the second quarter of 2021 of $4.5 billion, in addition to the $2 billion previously taken, it said.

Write to Ed Frankl at [e-mail]

(END) Dow Jones Newswires

06-21-22 1016ET